An open-label, parallel-group, multi-centre study to determine the effect of treatment with esomeprazole for six months on histological markers of esophageal epithelial acid-related disease in patients with upper GI (gastrointestinal) symptoms

Trial Profile

An open-label, parallel-group, multi-centre study to determine the effect of treatment with esomeprazole for six months on histological markers of esophageal epithelial acid-related disease in patients with upper GI (gastrointestinal) symptoms

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2008

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Dyspepsia; Gastro-oesophageal reflux; Heartburn
  • Focus Pharmacodynamics
  • Acronyms HEARD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 May 2008 Status changed from in progress to completed.
    • 10 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top